Carbonhand achieves regulatory approval in Australia
Carbonhand has been approved for sales in Australia after achieving Australian regulatory approval with listing on the Australian Register of Therapeutic Goods from 1 March 2023. With the approval, Bioservo's Australian distributor has started the sales process and has already initiated the prescription process to the first patients.
The Australian market has several generous reimbursement schemes for people in need of assistive devices. In addition to the national compensation system NDIS (National Disability Insurance Scheme) for people with disabilities, there are specific schemes for, for example, elderly people, people injured in workplace accidents, war veterans, etc. Now that Carbonhand is listed as a medical device, sales in Australia can really begin.
"Our distributor, Base Medical, has received the first of their 10 ordered Carbonhand demonstration systems and has since the beginning of the year approached clinics and healthcare professionals around Australia. There is a great interest in how Carbonhand can help people with different types of impaired hand function", says Petter Bäckgren, CEO of Bioservo and continues, "We and our distributor, Base Medical, believe that there is a great potential in the Australian market".
For more information, please contact
Petter Bäckgren, VD, Bioservo Technologies AB
Phone: +468 21 17 10
Mikael Wester, Marknadsdirektör, Bioservo Technologies AB
Phone: +468 21 17 10
About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.
FNCA Sweden AB is the company’s Certified Adviser on Nasdaq First North.
For more information, please visit www.bioservo.com